Core Insights - The Scripps Research Institute has developed a new imaging technology called vCATCH, which allows for precise localization of drug interactions at the single-cell level, aiding in the discovery of drug side effects [1][2] Group 1: Technology Overview - vCATCH technology illuminates the binding sites of drugs with single-cell precision, addressing the limitations of traditional methods that only show general organ distribution and overall drug concentration [1] - The technology is particularly applicable to covalent drugs that permanently bind to their targets [1] Group 2: Research Findings - In validation experiments, the team created binding maps for the cancer drugs ibrutinib and afatinib, revealing that ibrutinib binds not only to target cells in the blood but also to immune cells in the liver, heart tissue, and blood vessels, which may explain potential side effects like arrhythmia and bleeding [2] - The team is currently exploring whether vCATCH can enable cancer drugs to more selectively target tumor cells and is also studying the mechanisms of antidepressants in the brain [2] Group 3: Future Implications - The technology is expected to become a powerful tool for testing candidate drugs, ensuring strong binding to targets while minimizing adverse interactions in other organs, thereby reducing potential risks in early drug development [2]

Core Viewpoint - The article discusses the inclusion of a new indication for the drug Vomeletinib, which is intended for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations, as a breakthrough therapy [1][4]. Group 1: Drug Information - Vomeletinib is a third-generation EGFR-TKI that has previously been approved for two indications in China, targeting adult patients with EGFR mutations in NSCLC for second-line and first-line treatments [6]. - The new indication for Vomeletinib targets approximately 70 subtypes of EGFR PACC mutations, which account for about 12.5% of all EGFR mutation NSCLC patients, and currently, there are no approved drugs for this specific mutation in China [3][6]. Group 2: Clinical Research - The FURMO-002 study is the first prospective study globally to evaluate the efficacy and safety of Vomeletinib in treating NSCLC patients with EGFR PACC mutations [3][6]. - As of June 2025, the study reported an objective response rate (ORR) of 81.8% and a confirmed ORR of 68.2% for Vomeletinib at a dosage of 240 mg, with a disease control rate (DCR) of 100%, a median duration of response (DOR) of 14.6 months, and a median progression-free survival (PFS) of 16.0 months [7]. Group 3: Financial Performance - Vomeletinib is a major revenue source for the company, with sales increasing year-on-year. In 2024, the total revenue from Vomeletinib reached 3.506 billion yuan, representing a year-on-year growth of 77.27% [4][7]. - In the first half of 2025, Vomeletinib continued to show strong growth, achieving product sales revenue of 2.36 billion yuan, a nearly 51% increase compared to the previous year [7].

Core Viewpoint - The recent approval of multiple innovative drugs in China and favorable policies have led to a surge in interest in the Hong Kong innovative drug sector, with several ETFs in the pharmaceutical space seeing gains of over 40% this year [1][2]. Company Overview - He Mei Pharmaceutical Co., Ltd. (referred to as "He Mei Pharmaceutical") has submitted an IPO application to the Hong Kong Stock Exchange, with a post-investment valuation of 3.9 billion RMB after completing six rounds of financing [1][2]. - The company, founded in 2002, focuses on developing small molecule drugs for autoimmune diseases and tumors, with a strong position in the development of treatments for psoriasis, Behçet's disease, and inflammatory bowel disease [1][2]. Financial Performance - As of the latest financial report, He Mei Pharmaceutical has not yet achieved profitability, with projected revenues of approximately 4.05 million RMB and 5.298 million RMB for 2023 and 2024, respectively, primarily from government subsidies [1][2]. - The company is expected to incur losses of approximately 156 million RMB and 123 million RMB for the same periods [1]. Product Pipeline - He Mei Pharmaceutical has developed seven small molecule drug candidates targeting unmet needs in autoimmune and tumor diseases, with four candidates in Phase II, III clinical trials, or NDA stages for 12 indications as of May 21, 2025 [2][3]. - The two core products include Mufemilast, a potential first-in-class treatment for psoriasis, and Hemay022, a dual-target EGFR/HER2 inhibitor for advanced breast cancer [4][8]. Mufemilast Details - Mufemilast is a novel PDE4B inhibitor with a favorable safety profile, showing potential for treating psoriasis patients with latent tuberculosis [4][5]. - The global psoriasis drug market is projected to reach 29.621 billion USD in 2024, with a compound annual growth rate of 9.19% from 2024 to 2029 [5][6]. Competitive Landscape - Despite Mufemilast's advantages, the psoriasis treatment market is highly competitive, with numerous new drugs entering the market, posing challenges for commercial success [8][11]. - Hemay022 is currently undergoing a Phase III clinical trial for advanced ER+/HER2+ breast cancer, facing competition from existing EGFR/HER2 inhibitors [8][9]. Financial Pressure - The company anticipates significant financial pressure due to high R&D expenditures, with projected investments of 123 million RMB and 97 million RMB for 2023 and 2024, respectively [10]. - As of December 31, 2024, the company is expected to hold approximately 150 million RMB in cash and cash equivalents, indicating a tight financial situation [10]. Conclusion - Overall, while He Mei Pharmaceutical's core product for psoriasis shows rapid progress, the intense market competition and ongoing high R&D costs may hinder its ability to attract capital market interest [11].